Filing Flows › Rigel Pharmaceuticals (RIGL) › Operating margin
Rigel Pharmaceuticals (RIGL) operating margin by quarter
Rigel Pharmaceuticals' operating margin was 21.1% in Q3 2026 (third quarter 2026), -8.8 pts from Q2 2026. Over the last 7 quarters it ranged from 20.2% (Q1 2026) to 60.1% (Q2 2025).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 21.1% | -8.8 pts | -19.8 pts |
| Q2 2026 | 30.0% | +9.7 pts | -30.1 pts |
| Q1 2026 | 20.2% | -13.0 pts | -3.7 pts |
| Q4 2025 | 33.2% | -7.7 pts | — |
| Q3 2025 | 40.9% | -19.2 pts | — |
| Q2 2025 | 60.1% | +36.1 pts | — |
| Q1 2025 | 23.9% | — | — |
Q3 2026 at a glance
Rigel Pharmaceuticals, Q3 2026: revenue $80.9M (+16% year over year), operating margin 21.1%, net earnings $13.2M, operating cash flow $34.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Rigel Pharmaceuticals' operating margin?
Rigel Pharmaceuticals' operating margin was 21.1% in Q3 2026 (third quarter 2026), -8.8 pts from Q2 2026.
How has Rigel Pharmaceuticals' operating margin changed?
Over the last 7 quarters it ranged from 20.2% (Q1 2026) to 60.1% (Q2 2025).